Propelled by
Technological Change
Enzymit’s technology allows for unprecedented search of sequence space which is both expansive and focused. Protein sequence space is for even small proteins is intractable. There are over 10 possible sequence changes for any given protein. Experimental screening can only test upto
10 -10 enzyme variants in a single experiment. These experiments are extremely laborious, time consuming and not generalizable.
200
5
6
We Are Building a
Platform
ā
To improve existing enzyme functionality, at a fraction of the cost and time of alternative approaches.
To invent new enzymes to address unmet market needs.
The Enzyme
Conformation Space
Enzyme’s 3D structures define their function (their ability to work on the desired chemical) Each chemical requires the correct shape (conformation). To build new enzymes we need more structures. There are only a limited number of known enzyme structures (gathered from experiments). Compared to the vast protein sequence data
we have obtained through various genome projects.
Our Technology
Protein sequence space is for even small proteins is intractable. There are over 10 possible sequence changes for any given protein
200
Data gathered is fed into deep learning algorithms for continuous optimization of our enzyme design pipeline
Computational protein
design algorithms for new
chemistry enzyme design
Novel, proprietary experimental tools for high throughput testing of enzyme variants
Our Founders
_edited_edit.jpg)
Dror Baran
Co-founder, COO and VP
R&D (Biologics)
-
MSc, computational protein design - Weizmann Institute of Science.
-
Protein engineering and molecular biology expert.
-
Former Innovation Project Manager and Process Engineer at Biolojic Design.
-
Former Founding Scientist at IgC - led the experimental platform development.
Gideon Lapidoth
Co-founder, CEO and
CTO
-
PhD, computational protein design - Weizmann Institute of Science.
-
Developed computational algorithms for building novel antibodies and enzymes with high accuracy and activity.
-
Former Analyst at Yeda R&D (WIS).
-
Former infantry platoon commander in the IDF.
Our Board
Prof. Joseph Jacobson
Scientific Advisor
-
Tenured professor at MIT
-
Head of the Molecular Machines group at the Center for Bits and Atoms at the MIT Media Lab
-
World expert in synthetic biology
-
Contributes to the scientific development of the platform
Dr. Devin Leake
Business Advisor
-
Ph.D. in Molecular Biology and Biochemistry from the SUNY Stony Brook
-
Former head of DNA Synthesis at Ginkgo Bioworks
-
Has over one hundred issued patents and more than thirty publications in the area of nucleic acid biology
Our Team
Lior Zimmerman
Head of Computational Design
-
MSc in bioinformatics from the Hebrew University.
-
An expert in bioinformatics with a specialization in machine-learning.
-
Founding scientists at IgC - developed novel algorithms for antibody design.
Nufar Shpigel
R&D Scientist
-
Ph.D. in Life Sciences, Ben-Gurion University
-
Broad scientific knowledge in the field of protein folding in-vivo, with specialization in molecular biology, molecular genetics, biochemistry, and cell biology
-
Former scientist at Smart Assays.
Josh Jacobson
Business Development Manager
-
BA in Business Administration and Economics, Interdisciplinary Center Herzliya (Senior).
-
Former Investment Analyst at OurCrowd.
-
IDC Investment Management Group member.
-
Former IDF special forces.
Send Us a message
Copyright 2020 Enzymit Ltd. All Rights Reserved.
Pinhas Sapir Street 3, Daren labs, Ness Ziona - Science Park, 7403626